NCT05244837

Predictive Biomarker for Efficacy and Safety of Combination of Chemotherapy and Tislelizumab in NSCLC

Predictive Biomarker for the Efficacy and Safety of the Combination of Chemotherapy and Tislelizumab in Non Small Cell Lung Cancer：a Multicentre Prospective Clinical Trial

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: Hao Long · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

To explore the related biomarkers for safety and efficacy of the combination of chemotherapy and tislelizumab in non-small cell lung cancer

Conditions

• Tislelizumab
• Safety
• Biomarker
• Chemotherapy

Interventions

Type	Name	Description
DRUG	Tislelizumab 200 mg	Tislelizumab 200mg IV Q3W + Followed by adjuvant treatment for 1 year (Tislelizumab 200 mg IV Q3W for 2 cycles and Tislelizumab 200 mg Q4W for 12 cycles)
DRUG	Carboplatin AUC 5	Carboplatin AUC 5 IV Q3W
DRUG	pemetrexed 500mg/m2	Pemetrexed 500mg/m2 IV Q3W if non-squamous lung cancer
DRUG	Paclitaxel 175mg/m2	Paclitaxel 175mg/m2 IV Q3W if squamous lung cancer
DRUG	Nab-paclitaxel 260 mg/m2	nab-paclitaxel 260 mg/m2 Q3W if squamous lung cancer

Timeline

• Start date: 2020-12-22
• Primary completion: 2022-07-01
• Completion: 2023-12-01
• First posted: 2022-02-17
• Last updated: 2022-02-17

Locations

4 sites across 1 country: China